Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
IoGen clinical trial to focus on proliferative benign breast disease
November 24th, 2005
Symbollon Pharmaceuticals, Inc. (SYMBA) announced its intention to start a clinical trial that will focus on the treatment of patients with proliferative benign breast disease. The open-label, single-center study will evaluate the clinical effects of IoGen, an oral dosage form of Symbollon's proprietary molecular iodine technology, in about 20 women. Patients will receive one 6.0 mg tablet of IoGen daily for 1 year. The primary objective of this study is the evaluation of the effect of IoGen in patients who have benign proliferative breast disease. The response of the mammary gland to IoGen will be objectively evaluated using PET tomography scanner....
Source: Women's Health Weekly (2005-11-24)
|
